Biocytogen is committed to developing innovative antibody drugs that meet the needs of patients, focusing on oncology, autoimmune, inflammatory, metabolic and and other diseases. Taking full advantage of its unique advantage in innovative drug development, the company now has more than 10 R & D pipelines including monoclonal antibodies, bispecific antibodies, ADC drugs and so on. Our pipeline is supported by a strong clinical development team and abundant clinical resources.
Therapeutic Area |
Products |
Target |
Molecular Format |
Indication |
Status |
News/Press Release |
Partner |
Oncology |
YH001 | CTLA-4 | Monoclonal antibody | Solid Tumor | Phase 1-Phase 2 | Findings From Anti-CTLA-4 mAb Clinical Trials | |
| YH003 | CD40 | Monoclonal antibody | Solid Tumor | Phase 1-Phase 2 | Findings From Anti-CD40 Clinical Trials | ||
| YH002 | OX40 | Monoclonal antibody | Solid Tumor | Phase 1 | |||
| YH004 | 4-1BB | Monoclonal antibody | IND | ||||
| YH008 | PD-1/CD40 | Bi-specific antibody | Pre-clinical | ||||
| YH005 | CLDN18.2 | Antibody Drug Conjugate | Solid Tumor | IND | Remegen | ||
| YH006 | CTLA-4/OX40 | Bi-specific antibody | Solid Tumor | Discovery | |||
| YH010 | PD-L1/IL-12 | Bi-specific antibody | Solid Tumor | Discovery | |||
| Infectious Diseases | YH007 | SARS-CoV-2 | mAb cocktail | Pre-clinical | RenMab Platform Drives SARS-CoV2 mAb Cocktail Therapy | ||
| YH009 | RSV | Monoclonal antibody | Pre-clinical |
